Celcuity Inc. (CELC)
$
77.16
-1.80 (-2.33%)
Key metrics
Financial statements
Free cash flow per share
-1.9407
Market cap
1.9 Billion
Price to sales ratio
15.8 Thousand
Debt to equity
2.2403
Current ratio
4.5844
Income quality
0.5685
Average inventory
0
ROE
-1.5007
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Celcuity Inc., a clinical stage biotechnology company focused on developing molecularly targeted therapies for cancer patients in the United States, reported an income before tax of -$111,779,105.00 showcasing its pre-tax profitability. Despite this positive indication, the company reported a net loss of -$111,779,105.00 indicating challenges in its operations. The earnings per share (EPS) is reported at -$2.83 which highlights the company's profitability on a per-share basis. Additionally, the company reported depreciation and amortization expenses of $129,947.00 reflecting the wear and tear of its assets. The income before tax ratio stands at 0.00 reflecting the pre-tax margin. Celcuity's CELsignia diagnostic platform allows for the identification of specific abnormal cellular processes in patients’ cancer using their living tumor cells, enabling targeted therapy selection. Among its drug candidates, Gedatolisib selectively targets various class I isoforms of PI3K and mammalian target of rapamycin, particularly focusing on hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also advancing the CELsignia MP test, a qualitative laboratory-developed test to measure HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Furthermore, Celcuity has a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Founded in 2011 and headquartered in Minneapolis, Minnesota, the company operates within a crucial and transformative landscape of cancer treatment. In terms of its market positioning, the stock is affordable at $51.88 making it suitable for budget-conscious investors. With a low average trading volume of 1,155,046.00 the stock indicates lower market activity, suggesting a potentially less volatile investment environment. With a market capitalization of $3,273,535,839.00 the company is classified as a small-cap player in the industry, where it is recognized as a key contributor shaping the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth, providing promising avenues for investment as it continues to develop its targeted therapies and diagnostic platforms.
Is Celcuity Inc. (CELC) a good investment?
Investing in Celcuity Inc. (CELC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Celcuity Inc. (CELC)'s stock forecast?
Analysts predict Celcuity Inc. stock to fluctuate between $7.58 (low) and $83 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Celcuity Inc.'s market capitalization?
As of 2025-10-31, Celcuity Inc.'s market cap is $3,273,535,839, based on 42,425,296 outstanding shares.
How does Celcuity Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Celcuity Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Celcuity Inc. (CELC) stock?
To buy Celcuity Inc. (CELC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CELC. Place an order (Market, Limit, etc.).
What is the best time to invest in Celcuity Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Celcuity Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.83 | Growth: 5.20%.
Where can I find Celcuity Inc.'s investor relations reports?
Visit https://www.celcuity.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Celcuity Inc.?
You can explore historical data from here
What is the all-time high and low for Celcuity Inc. stock?
All-time high: $83 (2025-10-20) | All-time low: $4.81 (2022-05-17).
What are the key trends affecting Celcuity Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Celcuity Inc. remains a Strong Buy, driven by positive Phase 3 VIKTORIA-1 data for gedatolisib in 2nd-line PIK3CA wild type HR+/HER2- advanced breast cancer patients. Company expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025, targeting wild-type PIK3CA advanced breast cancer patients. CELC can potentially move to targeting 1st-lne PIK3CA mutant and wild-type HR+/HER2- advanced breast cancer patients with ongoing phase 3 VIKTORIA-2 study.
seekingalpha.com
Celcuity Inc. (NASDAQ:CELC ) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting October 20, 2025 8:00 AM EDT Company Participants Brian Sullivan - Co-Founder, Chairman & CEO Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Tara Bancroft - TD Cowen, Research Division Andrew Berens - Leerink Partners LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Gil Blum - Needham & Company, LLC, Research Division Presentation Operator Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today.
globenewswire.com
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updates on the status of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus alpelisib and fulvestrant in adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutant (“MT”) tumors, locally advanced or metastatic breast cancer, following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. Analysis of data from a Phase 1b clinical trial that evaluated gedatolisib combined with palbociclib and fulvestrant in the same population was also provided.
seekingalpha.com
Celcuity (CELC) surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer, affirming commercial potential. Gedatolisib shows significant progression-free survival benefits in VIKTORIA-1, with manageable discontinuation rates and a $5B market opportunity targeted by CELC. Recent fundraising and loan facilities secure CELC's cash runway into 2027, supporting NDA filing, potential approval, and initial launch.
globenewswire.com
MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025. The presentation will provide detailed efficacy and safety data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial.
seekingalpha.com
Celcuity Inc. (NASDAQ:CELC ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Brian F. Sullivan - Co-Founder, Chairman & CEO Vicky Hahne - Chief Financial Officer Conference Call Participants Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Eason Lee - Leerink Partners LLC, Research Division Frances Dovell - TD Cowen, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division Mohamad Amin Makarem - Jefferies LLC, Research Division Stephen Douglas Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Apoorva Chaloori - Unidentified Company Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2025 Financial Results Webcast and Conference Call.
seekingalpha.com
Celcuity's phase 3 VIKTORIA-1 trial showed gedatolisib significantly improved progression-free survival in PIK3CA wild-type HR+/HER2- advanced breast cancer patients. NDA submission for gedatolisib in 2nd-line PIK3CA wild-type HR+/HER2- ABC patients is planned for Q4 2025, with expansion to mutant and 1st-line cohorts underway as well. Strong market opportunity exists as HR+/HER2- breast cancer represents 70% of all breast cancers; Data from PIK3CA-mutant cohort expected by end of 2025.
globenewswire.com
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public offering of $175,000,000 aggregate principal amount of its 2.750% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”), and its underwritten public offering of 1,836,842 of shares of its common stock (the “Common Stock”) at a public offering price of $38.00 per share and, in lieu of Common Stock to investors who so choose, pre-funded warrants to purchase up to 400,000 shares of Common Stock (the “Pre-Funded Warrants”) at a public offering price of $37.999 per Pre-Funded Warrant, which represents the per share public offering price of each share of Common Stock less the $0.001 per share exercise price of each Pre-Funded Warrant (such offering, the “Common Stock Offering”).
forbes.com
Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single trading session, with shares rocketing from approximately $14 to a peak of $46 before stabilizing around $37. This dramatic price movement was triggered by positive topline results from the PIK3CA wild-type cohort of the company's Phase 3 VIKTORIA-1 clinical trial for gedatolisib, a targeted therapy for HR+/HER2- breast cancer.
invezz.com
Shares of Celcuity surged more than 186% on Monday after the biotechnology company reported highly positive topline results from a Phase 3 clinical trial of its investigational breast cancer treatment. The stock was set for its best day on record if it held the gains.
See all news
